Our lead investigative pharmaceutical product is iloprost and it is currently in clinical development. Our aim is to achieve the reduction of moderate to severe lung dysplasia as measured by the LuCED® lung test, and to qualify iloprost as a first-in-class lung cancer chemoprevention treatment. Iloprost, an oral prostacyclin analog, has progressed through an NCI-sponsored Phase 2 clinical trial and achieved a significant reduction in bronchial dysplasia. Iloprost will be developed with the LuCED® lung test as its companion diagnostic. VisionGate is also evaluating iloprost clinical development opportunities for the prevention of lung cancer in high-risk patients and the prevention of lung cancer recurrence in early stage lung cancer patients.
Lung Cancer Pioneers Create Lung Cancer Eradication Pact: VisionGate Acquires Exclusive Rights to University of Colorado’s Chemoprevention Drug Iloprost – Partnership Would Combine Company’s Patented Technology that Detects Precancer of the Lungs with Drug Treatment that Prevents Cancer
PHOENIX, Ariz. (January 7, 2016) – VisionGate, Inc., an emerging biotech company in the early lung cancer detection space today announced it has acquired exclusive rights to the University of Colorado’s patent for the use of the drug Iloprost in the prevention of lung cancer, making it one of the first companies to evolve from a diagnostic company to a synergistic diagnostic and therapeutic company.
READ MORE: Complete Press Release